Elanco Animal Health has expanded the FDA‑approved labels for its canine parasiticides Credelio Quattro and Credelio to include claims for prevention of Lyme disease and protection against the longhorned tick (Haemaphysalis longicornis). The update applies to the lotilaner‑based products: Credelio Quattro, which contains lotilaner, moxidectin, praziquantel, and pyrantel, and Credelio, which contains single‑ingredient lotilaner.
The FDA revision, dated 2025‑10‑24, added the Lyme disease prevention claim as a result of killing black‑legged ticks (Ixodes scapularis) and the longhorned tick protection claim, reflecting the species’ established presence in 22 U.S. states and its capacity to transmit canine pathogens such as Ehrlichia and Babesia.
Credelio and Credelio Quattro already provide protection against several tick species, including the lone star tick (Amblyomma americanum), American dog tick (Dermacentor variabilis), black‑legged tick, and brown dog tick (Rhipicephalus sanguineus). The new label expands coverage to include Lyme disease prevention through the elimination of black‑legged ticks.
According to the Companion Animal Parasite Council, more than 422,000 cases of Lyme disease have been reported in dogs in the United States in 2025, surpassing the total number of cases seen in 2019. The longhorned tick, an invasive species first confirmed in the U.S. in 2017, is now established in 22 states and is known to transmit canine pathogens and is associated with alpha‑gal syndrome in humans.
Safety information: Lotilaner, an isoxazoline class active ingredient, has been associated with neurologic adverse reactions such as tremors, incoordination, and seizures, even in dogs without a history of seizures. Veterinarians are advised to use caution in dogs with a history of seizures or neurologic disorders.
The label expansion aligns with Elanco’s strategy to deliver differentiated preventive products and may enhance adoption by veterinarians and pet owners in high‑risk regions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.